EP Patent

EP4012031A1 — Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded rna

Assigned to Novo Nordisk AS · Expires 2022-06-15 · 4y expired

What this patent protects

This invention relates to compounds, compositions and methods useful for reducing α-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g. Dicer substrate siRNA (DsiRNA) agents.

USPTO Abstract

This invention relates to compounds, compositions and methods useful for reducing α-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g. Dicer substrate siRNA (DsiRNA) agents.

Drugs covered by this patent

Patent Metadata

Patent number
EP4012031A1
Jurisdiction
EP
Classification
—
Expires
2022-06-15
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.